Park Jiesuck, Yoon Yeonyee Elizabeth, Kim Kyoung Min, Hwang In-Chang, Lee Wonjae, Cho Goo-Yeong
Department of Cardiology, Cardiovascular Center, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Republic of Korea.
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
Heart. 2021 Jun 11;107(13):1040-1046. doi: 10.1136/heartjnl-2020-318764.
We investigated whether the evaluation of bone mineral density (BMD) provides independent and incremental prognostic value for predicting atherosclerotic cardiovascular disease (ASCVD) in women.
A total of 12 681 women aged 50-80 years (mean, 63.0±7.8 years) who underwent dual-energy X-ray absorptiometry were retrospectively analysed. We assessed the hazard ratio (HR) for ASCVD events (ASCVD death, non-fatal myocardial infarction and ischaemic stroke) according to the BMD or a clinical diagnosis of osteopenia or osteoporosis, with adjustment for clinical risk factors, including age, body mass index, hypertension, type 2 diabetes, hyperlipidaemia, current smoking and previous fracture. We also evaluated whether the addition of BMD or a clinical diagnosis of osteopenia or osteoporosis to clinical risk factors improved the prediction for ASCVD events.
In total, 468 women (3.7%) experienced ASCVD events during follow-up (median, 9.2 years). Lower BMD at the lumbar spine, femur neck and total hip was independently associated with higher risk for ASCVD events (adjusted HR per 1-standard deviation decrease in BMD: 1.16, p<0.001; 1.29, p<0.001; 1.38, p<0.001; respectively). A clinical diagnosis of osteoporosis was also independently associated with higher risk for ASCVD events (adjusted HR: 1.79, p<0.001). The addition of BMD or a clinical diagnosis of osteopenia or osteoporosis to clinical risk factors demonstrated significant incremental value in discriminating ASCVD events (addition of total hip BMD, p for difference <0.001).
The evaluation of BMD provides independent and incremental prognostic value for ASCVD in women and thus may improve risk stratification in women.
我们研究了骨密度(BMD)评估对于预测女性动脉粥样硬化性心血管疾病(ASCVD)是否具有独立且递增的预后价值。
对总共12681名年龄在50 - 80岁(平均63.0±7.8岁)且接受了双能X线吸收测定法的女性进行了回顾性分析。我们根据BMD或骨质疏松症或骨质减少的临床诊断评估了ASCVD事件(ASCVD死亡、非致命性心肌梗死和缺血性中风)的风险比(HR),并对包括年龄、体重指数、高血压、2型糖尿病、高脂血症、当前吸烟和既往骨折在内的临床风险因素进行了调整。我们还评估了将BMD或骨质疏松症或骨质减少的临床诊断添加到临床风险因素中是否能改善对ASCVD事件的预测。
总共有468名女性(3.7%)在随访期间(中位数为9.2年)发生了ASCVD事件。腰椎、股骨颈和全髋部较低的BMD与ASCVD事件的较高风险独立相关(BMD每降低1个标准差的调整后HR分别为:1.16,p<0.001;1.29,p<0.001;1.38,p<0.001)。骨质疏松症的临床诊断也与ASCVD事件的较高风险独立相关(调整后HR:1.79,p<0.001)。将BMD或骨质疏松症或骨质减少的临床诊断添加到临床风险因素中在区分ASCVD事件方面显示出显著的递增价值(添加全髋部BMD,差异p<0.001)。
BMD评估为女性ASCVD提供了独立且递增的预后价值,因此可能改善女性的风险分层。